Article Text

Download PDFPDF

LP-072 Validity of a claim-based algorithm for SLE disease severity to clinical SLE disease activity index in Korean patients with SLE
  1. Hyoungyoung Kim1,
  2. Eunwoo Nam1,
  3. Sun-Young Jung2,
  4. Eun Jin Jang3,
  5. Yoon-Kyoung Sung1 and
  6. Soo-Kyung Cho1
  1. 1Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Republic of Korea
  2. 2College of Pharmacy, Chung-Ang University, Republic of Korea
  3. 3Department of Information Statistics, Andong National University, Republic of Korea


Background Previous US study presented a claims-based algorithm, consisted with comorbidities and medication information, to classify systemic lupus erythematosus (SLE) severity as mild, moderate or severe. We aimed to validate algorithms to measure SLE activity in Korean claims data.

Methods We identified SLE patients in a single academic hospital between October 2014 and August 2020. To measure SLE disease activity, we set five algorithms using diagnostic codes for comorbidities and medications: (1) previously suggested algorithm consisted of SLE-related comorbidities, immunosuppressant including rituximab, cyclophosphamide, etc., and oral glucocorticoid, (2) modified (1) by adding intravenous glucocorticoid, (3) modified (1) by adjusting glucocorticoid criteria with 55mg to differentiate between moderate and severe SLE, (4) modified (1) by adjusting glucocorticoid criteria with 5mg to differentiate between mild and moderate SLE, (5) combined algorithm (3) with (4), We assessed SLE Disease Activity Index-2000 (SLEDAI-2K) score at each visit over a year per person, and calculated average SLEDAI-2K for 1 year as gold standard. After categorizing moderate to severe ≥ 3 of SLEDAI-2K, sensitivity, specificity, positive predictive values (PPV), and negative predictive values for the algorithms to detect patients with moderate to severe SLE were estimated.

Results We included 151 patients with SLE. Their mean age was 34.5 ± 8.8, and 94.7% were female, presenting initial SLEDAI-2K score of 3.8 ± 3.2. For classifying moderate to severe SLE, the PPV of claims-based algorithm ranged from 75.86 to 77.19%. The algorithms (4) and (5) improved PPV up to 77.19%. However, the algorithms modifying glucocorticoid dose to differentiate between moderate and severe SLE or considering any prescriptions of intravenous glucocorticoid did not increase the PPV.

Conclusions The algorithm using diagnostic codes for comorbidities and medications demonstrated PPV of 77.19% to detect moderate to severe SLE. It may be a useful for classifying SLE severity in Korean claims database studies.

  • Systemic lupus erythematosus
  • Disease severity
  • Algorithm

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.